Population modelling of patient responses in antidepressant studies: a stochastic approach.
暂无分享,去创建一个
Stefano Zamuner | Roberto Gomeni | Giuseppe De Nicolao | Eleonora Marostica | Alberto Russu | G. De Nicolao | R. Gomeni | S. Zamuner | A. Russu | E. Marostica
[1] J. L. Steimer,et al. Variability in drug therapy : description, estimation, and control : a Sandoz workshop , 1985 .
[2] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[3] A. Miller,et al. Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.
[4] Giuseppe De Nicolao,et al. Nonparametric input estimation in physiological systems: Problems, methods, and case studies , 1997, Autom..
[5] Italo Poggesi,et al. Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity , 2009, Expert opinion on drug discovery.
[6] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[7] An Vermeulen,et al. Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders , 2011, Clinical pharmacokinetics.
[8] Giuseppe De Nicolao,et al. Nonparametric identification of population models via Gaussian processes , 2007, Autom..
[9] R. Gomeni,et al. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.
[10] D R Mould,et al. Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.
[11] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[12] Michael Krams,et al. Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[13] Giuseppe De Nicolao,et al. Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches , 2011, IEEE Transactions on Biomedical Engineering.
[14] Andrew P Grieve,et al. Implementation of a Bayesian adaptive design in a proof of concept study , 2006, Pharmaceutical statistics.
[15] Stefano Zamuner,et al. A PCA approach to population analysis: with application to a Phase II depression trial , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[16] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[17] Michael D. Smith,et al. Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .
[18] Dennis V. Lindley,et al. Principles of Random Walk. , 1965 .
[19] Nonparametric AUC Estimation in Population Studies with Incomplete Sampling: A Bayesian Approach , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[20] H. Robbins. An Empirical Bayes Approach to Statistics , 1956 .
[21] Meindert Danhof,et al. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. , 2008, Journal of psychiatric research.